The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2019Identifying Protein Sequence of Potential Drug Target Synuclein Nitrase
Study Rationale:
We have found that alpha-synuclein nitration and aggregation — which may play a role in Parkinson’s disease — is catalyzed by an enzyme that we have termed synuclein nitrase. In this... -
Target Advancement Program, 2019Chaperone-mediated Autophagy to Counteract Alpha-synuclein Pathology
Study Rationale:
A hallmark of Parkinson’s disease (PD) is aggregates of the protein alpha-synuclein. One of the main pathways to remove excess amounts of alpha-synuclein, which can be toxic for the... -
Research Grant, 2019Parkinson’s Digital Biomarker DREAM Challenges to Develop Measures of Symptoms and Severity
Study Rationale:
The use of wearable sensors to detect and measure Parkinson’s disease shows great promise. However how to convert the raw data to specific measures is poorly understood. We propose a... -
Research Grant, 2019Tool to Identify Parkinson’s Disease Using Digital Facial Expression Biomarkers
Study Rationale:
Traditional Parkinson’s disease (PD) detection and monitoring systems lack objective biomarkers and are often reliant on late-stage symptoms. By contrast, a masked face is often seen... -
Research Grant, 2019Pre-formed Fibril-seeded Synucleinopathy: Impact on Proinflammatory Cytokines and Contralateral Excitotoxicity
Promising Outcomes of Original Grant:
We have successfully characterized the time course and magnitude of alpha-synuclein aggregation and neurodegeneration of the nigrostriatal system following... -
Research Grant, 2019Biologically Meaningful Modulation of Alpha-synuclein Expression via Clenbuterol
Promising Outcomes of Original Grant:
The drug clenbuterol, a beta-2 adrenoreceptor agonist, has been shown to decrease alpha-synuclein expression and to be neuroprotective in some models. Our results...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.